Swedish Study Reveals Why CGM Makes Life Better for Type 1 Diabetes Patients

A study from Sweden has uncovered a surprising truth about continuous glucose monitors (CGM): the biggest reason people with Type 1 diabetes feel better using them has less to do with improved blood sugar numbers and more to do with the freedom and convenience these devices provide in daily life.

Researchers at the University of Gothenburg's Sahlgrenska Academy analyzed data from the landmark GOLD trial — a rigorous randomized crossover study that followed 139 adults with Type 1 diabetes for 16 months. Participants alternated between using CGM and traditional self-monitored blood glucose (SMBG) finger-stick testing. The Swedish team then dug deeper to understand why CGM users felt so much better.

What the Research Found

The results were eye-opening. A full 60% of the improvement in treatment satisfaction came from the increased convenience and flexibility CGM provided — the ability to check glucose levels discreetly, set alerts, and reduce the burden of constant finger-sticking. By contrast, perceived improvements in hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) control accounted for only 6% of that satisfaction boost.

Participants using CGM also reported meaningful improvements in day-to-day well-being, including feeling:

• More cheerful
• Calmer and more relaxed
• More physically active
• Better rested upon waking

On the clinical side, CGM users did show real glucose improvements. Better HbA1c levels and increased Time in Range (TIR) — the percentage of the day blood sugar stays between 70–180 mg/dL (the US standard target, equivalent to 3.9–10.0 mmol/L) — were both linked to higher treatment satisfaction. Higher TIR was also associated with less diabetes-related emotional distress. Notably, glucose variability alone was not a significant driver of satisfaction.

Why a Swedish Perspective Matters for US Patients

Sweden maintains one of the world's most comprehensive national diabetes registries and has high CGM adoption rates among people with Type 1 diabetes. This gives Swedish researchers a unique vantage point for studying long-term, real-world outcomes — beyond what shorter US studies can capture. The GOLD trial's crossover design, where each participant served as their own control, is particularly rigorous, reducing variables that could skew results.

How This Compares to US Guidelines

The American Diabetes Association (ADA) already recommends CGM for most people with Type 1 diabetes, citing glucose control benefits. However, US insurance coverage decisions and clinical conversations often center on HbA1c improvements as the primary justification. This Swedish research suggests that quality-of-life and lifestyle benefits deserve equal weight in those conversations — and may actually be more meaningful to patients day-to-day.

Why This Matters for US Patients

If you or someone you love has Type 1 diabetes and is considering CGM — or fighting an insurance denial — this research offers powerful evidence beyond the numbers. The case for CGM isn't only about getting your A1c down. It's about sleeping better, feeling calmer, and reclaiming flexibility in your life. Talk to your endocrinologist about documenting quality-of-life impacts when advocating for CGM coverage. The science now backs you up.

Original Study: Pylov, Polonsky, Imberg. "Treatment Satisfaction and Well-Being With Continuous Glucose Monitoring in People With Type 1 Diabetes: An Analysis Based on the GOLD Randomized Trial." Journal of Diabetes Science and Technology, 2025. PMID: 37501366. DOI: 10.1177/19322968231183974